Analysis of cancer incidence and mortality data in Heilongjiang province cancer registries, China, 2015

Objective In recent years, the rising incidence of cancer has increased patients’ living and economic burdens. This study analyzed the incidence and death due to malignant tumors in tumor registries in Heilongjiang province (China) in 2015 to provide a scientific basis for the prevention and treatment of malignant tumors in this province. Methods Data on tumor incidence and patient deaths were collected from seven tumor registries in Heilongjiang province (China) in 2015. According to the stratification of urban and rural areas and patient sex, the crude, standard, and accumulative rates (0–74 years of age) were calculated. The 2000 China Population Census data and Segi’s standard population were used to calculate the age-standardized rates. Results In 2015, the incidence rate of malignant tumors in Heilongjiang cancer registries was 259.90/100 000. The age-standardized incidence rates in the Chinese and world standard populations were 158.89/100 000 and 155.06/100 000, respectively, with a cumulative incidence rate (0–74 years) of 17.68%. The incidence of malignant tumors in urban areas was 273.55/100 000, while that in rural areas was 220.32/100 000. The incidence of malignant tumors in men was 270.89/100 000, higher than that in women (249.04/100 000). Lung cancer had the highest incidence, followed by breast cancer, liver cancer, colorectal cancer, and thyroid cancer. The mortality rate of malignant tumors in Heilongjiang cancer registries was 164.69/100 000. The age-standardized mortality rates in Chinese and in world standard populations were 95.29/100 000 and 94.35/100 000, respectively, with a cumulative mortality rate (0–74 years) of 10.44%. The mortality rate of malignant tumors in urban areas was 169.51/100 000, while that in rural areas was 150.72/100 000. The mortality rate of malignant tumors in men was 201.64/100 000, higher than that in women (128.21/100 000). Lung cancer had the highest mortality, followed by liver cancer, stomach cancer, colorectal cancer, and breast cancer. Conclusion Lung, liver, breast, and colorectal cancers were the most common cancers in Heilongjiang province, China, and should be considered the key cancer types for prevention and treatment. Moreover, the incidence of thyroid cancer is increasing, and thus early preventative measures should be implemented.

Analysis of cancer incidence and mortality in Heilongjiang cancer registries, 2016

Background:Cancer incidence rate has been increasing in recent years,and it has improved people’s living and financial burden.The incidence and mortality of malignant tumors in the Heilongjiang cancer registry area in 2016 were analyzed,which provided a scientific basis for the prevention and treatment of malignant tumors in Heilongjiang.Methods:The incidence and death data of tumors were collected from 10 tumor registration areas in Heilongjiang Province in 2016.According to the stratification of urban and rural areas and gender,the crude rate,standard rate,accumulative rates(0–74 years old)were calculated.The China 2000 population census data and Segi’s standard population were used for calculating age-standardized rates.Results:The incidence rate of malignant tumors in the Heilongjiang cancer registry area was 286.05/100,000 in 2016,age-standardized incidence rates by standard Chinese population and by standard world population were 168.11/100,000 and 164.69/100,000 with the cumulative incidence rate(0–74 years old)of 18.55%.The incidence of malignant tumors in urban areas was 313.60/100,000,and that in rural areas was 212.26/100,000.The frequency of malignant tumors in males was 295.94/100,000,higher than that in females(276.40/100,000).Lung cancer had the highest incidence followed by breast cancer,colorectal cancer,liver cancer and thyroid cancer.The mortality rate of malignant tumors in Heilongjiang cancer registration areas was 183.56/100,000,age-standardized mortality rates by standard Chinese population and by standard world population were 99.89/100,000 and 99.78/100,000 with the cumulative mortality rate(0–74 years old)of 10.95%.The mortality rate of malignant tumors in urban areas was 194.69/100,000,and that in rural areas was 153.73/100,000.The mortality rate of the male malignant tumor was 222.55/100,000,higher than that of a female malignant tumor(145.51/100,000).Lung cancer had the highest mortality followed by liver cancer,colorectal cancer,gastric cancer and breast cancer.Conclusion:Lung cancer,liver cancer,breast cancer and colorectal cancer were the most common cancers in Heilongjiang Province,which should be taken as the key cancer species for prevention and treatment.The incidence of thyroid cancer is higher in Heilongjiang Province,but the mortality rate is lower,which also needs attention.

A case-control study about the association between vascular endothelial growth inhibitor gene polymorphisms and breast cancer risk in female patients in Northeast China

Objective： The inhibition of the neovascularization in tumors is a potential therapeutic target of cancer. Vascular endothelial growth inhibitor （VEGI） is a member of the TNF superfamily which has the ability to suppress the formation of new vessels in tumors. In order to study the association between VEGI gene polymorphisms and breast cancer risk, a case-control study was conducted in Chinese Han women in Northeast China. Methods： Our study involved 708 female breast cancer patients and 685 healthy volunteers. Four SNPs of VEGI gene were analyzed through the polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP） method. The association between VEGI gene polymorphisms and breast cancer risk was analyzed in our study. The relation between VEGI gene variants and clinical features of breast cancer including lymph node （LN） metastasis, esl^ogen receptor （ER）, progestrogen receptor （PR）, tumor protein 53 （1953）, human epidermal growth factor receptor 2 （Her-2） and triple negative （ER-/PR-/Her-2-） status was analyzed as well. Results： We found that the CT genotype and T allele of rs6478106 were more frequent in patients than in controls. There was also a statistical difference in the distribution of Crs6478106Grs4263839 haplotype between patients and controls. In addition, SNP rs6478106 and rs4979462 were related with the Her-2 status. Conclusions： Our results suggest that VEGI gene variants may be related to the breast cancer risk and the clinical features of breast cancer in Chinese Han women in Northeast China.

Bionic peptide scaffold in situ polarization and recruitment of M2 macrophages to promote peripheral nerve regeneration

Tissue regeneration requires exogenous and endogenous signals,and there is increasing evidence that the exogenous microenvironment may play an even more dominant role in the complex process of coordinated multiple cells.The short-distance peripheral nerve showed a spontaneous regenerative phenomenon,which was initiated by the guiding role of macrophages.However,it cannot sufficiently restore long-distance nerve injury by itself.Based on this principle,we firstly constructed a proinflammatory model to prove that abnormal M2 expression reduce the guidance and repair effect of long-distance nerves.Furthermore,a bionic peptide hydrogel scaffold based on self-assembly was developed to envelop M2-derived regenerative cytokines and extracellular vesicles(EVs).The cytokines and EVs were quantified to mimic the guidance and regenerative microenvironment in a direct and mild manner.The bionic scaffold promoted M2 transformation in situ and led to proliferation and migration of Schwann cells,neuron growth and motor function recovery.Meanwhile,the peptide scaffold combined with CX3CL1 recruited more blood-derived M2 macrophages to promote long-distance nerve reconstruction.Overall,we systematically confirmed the important role of M2 in regulating and restoring the injury peripheral nerve.This bionic peptide hydrogel scaffold mimicked and remodeled the local environment for M2 transformation and recruitment,favoring long-distance peripheral nerve regeneration.It can help to explicate regulative effect of M2 may be a cause not just a consequence in nerve repair and tissue integration,which facilitating the development of pro-regenerative biomaterials.

Role of LINC00152 in non-small cell lung cancer

Non-small cell lung cancer(NSCLC)accounts for about 85%of all lung cancer cases.The pathogenesis of NSCLC involves complex gene networks that include different types of non-coding RNAs,such as long non-coding RNAs(lnc RNAs).The role of lnc RNAs in NSCLC is gaining an increasing interest as their function is being explored in various human cancers.Recently,a new oncogenic lnc RNA,LINC00152(cytoskeleton regulator RNA(CYTOR)),has been identified in different tumor types.In NSCLC,the high expression of LINC00152 in tumor tissue and peripheral blood samples has been shown to be associated with worse prognoses of NSCLC patients.Overexpression of LINC00152 has been confirmed to promote the proliferation,invasion,and migration of NSCLC cells in vitro,as well as increase tumor growth in vivo.This review discusses the role of LINC00152 in NSCLC.

中国人群伤残权重测量:聚焦癌症,量化评估伤残权重对癌症疾病负担估计的影响

伤残权重对于量化评估非死亡相关健康损失至关重要.全球范围看,目前仅有少数国家或地区对伤残权重进行了评估,且极少有肿瘤特异性的伤残权重结果报道.本研究基于大样本人群估计中国人群肿瘤特异性伤残权重,并比较不同伤残权重对量化评估肿瘤疾病负担的影响.基于开放式网络调查,采用配对比较的方法进行伤残权重的测量.伤残寿命损失年(YLDs)估计为不同瘤种各时期肿瘤的患病人数与其对应时期的伤残权重乘积之和.研究共收集到44,069份有效调查问卷,估计了包含18类恶性肿瘤在内的254个健康状态的残疾权重.其中,诊断和初始治疗阶段的肿瘤特异性伤残权差异较大,脑瘤的伤残权重最高为0.619(95%不确定性区间(UI):0.606~0.632),口咽癌伤残权重最低,为0.167(95%UI:0.158~0.176).不同肿瘤伤残权重对YLDs估计影响较大,所有肿瘤合计的YLDs差异超过30%.本研究提供的肿瘤特异性伤残权重可以为精确估计肿瘤疾病负担提供重要的数据支持.